412 related articles for article (PubMed ID: 25561469)
21. MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma.
Pitolli C; Marini A; Guerra M; Pieraccioli M; Marabitti V; Palluzzi F; Giacò L; Tamburrini G; Cecconi F; Nazio F; Sette C; Pagliarini V
J Exp Clin Cancer Res; 2023 Aug; 42(1):214. PubMed ID: 37599362
[TBL] [Abstract][Full Text] [Related]
22. CDK12 loss in cancer cells affects DNA damage response genes through premature cleavage and polyadenylation.
Krajewska M; Dries R; Grassetti AV; Dust S; Gao Y; Huang H; Sharma B; Day DS; Kwiatkowski N; Pomaville M; Dodd O; Chipumuro E; Zhang T; Greenleaf AL; Yuan GC; Gray NS; Young RA; Geyer M; Gerber SA; George RE
Nat Commun; 2019 Apr; 10(1):1757. PubMed ID: 30988284
[TBL] [Abstract][Full Text] [Related]
23. CDK13 cooperates with CDK12 to control global RNA polymerase II processivity.
Fan Z; Devlin JR; Hogg SJ; Doyle MA; Harrison PF; Todorovski I; Cluse LA; Knight DA; Sandow JJ; Gregory G; Fox A; Beilharz TH; Kwiatkowski N; Scott NE; Vidakovic AT; Kelly GP; Svejstrup JQ; Geyer M; Gray NS; Vervoort SJ; Johnstone RW
Sci Adv; 2020 May; 6(18):. PubMed ID: 32917631
[TBL] [Abstract][Full Text] [Related]
24. Cyclin K goes with Cdk12 and Cdk13.
Kohoutek J; Blazek D
Cell Div; 2012 Apr; 7():12. PubMed ID: 22512864
[TBL] [Abstract][Full Text] [Related]
25. CDK12 controls G1/S progression by regulating RNAPII processivity at core DNA replication genes.
Chirackal Manavalan AP; Pilarova K; Kluge M; Bartholomeeusen K; Rajecky M; Oppelt J; Khirsariya P; Paruch K; Krejci L; Friedel CC; Blazek D
EMBO Rep; 2019 Sep; 20(9):e47592. PubMed ID: 31347271
[TBL] [Abstract][Full Text] [Related]
26. Noncovalent CDK12/13 dual inhibitors-based PROTACs degrade CDK12-Cyclin K complex and induce synthetic lethality with PARP inhibitor.
Niu T; Li K; Jiang L; Zhou Z; Hong J; Chen X; Dong X; He Q; Cao J; Yang B; Zhu CL
Eur J Med Chem; 2022 Jan; 228():114012. PubMed ID: 34864331
[TBL] [Abstract][Full Text] [Related]
27. Discovery of MFH290: A Potent and Highly Selective Covalent Inhibitor for Cyclin-Dependent Kinase 12/13.
Liu Y; Hao M; Leggett AL; Gao Y; Ficarro SB; Che J; He Z; Olson CM; Marto JA; Kwiatkowski NP; Zhang T; Gray NS
J Med Chem; 2020 Jul; 63(13):6708-6726. PubMed ID: 32502343
[TBL] [Abstract][Full Text] [Related]
28. Role and therapeutic potential of CDK12 in human cancers.
Chilà R; Guffanti F; Damia G
Cancer Treat Rev; 2016 Nov; 50():83-88. PubMed ID: 27662623
[TBL] [Abstract][Full Text] [Related]
29. ARID1A loss promotes RNA editing of CDK13 in an ADAR1-dependent manner.
Zhu T; Li Q; Zhang Z; Shi J; Li Y; Zhang F; Li L; Song X; Shen J; Jia R
BMC Biol; 2024 Jun; 22(1):132. PubMed ID: 38835016
[TBL] [Abstract][Full Text] [Related]
30. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
31. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of the carboxy-terminal repeat domain in RNA polymerase II by cyclin-dependent kinases is sufficient to inhibit transcription.
Gebara MM; Sayre MH; Corden JL
J Cell Biochem; 1997 Mar; 64(3):390-402. PubMed ID: 9057097
[TBL] [Abstract][Full Text] [Related]
33. CDK12 and Integrator-PP2A complex modulates LEO1 phosphorylation for processive transcription elongation.
Qiu M; Yin Z; Wang H; Lei L; Li C; Cui Y; Dai R; Yang P; Xiang Y; Li Q; Lv J; Hu Z; Chen M; Zhou HB; Fang P; Xiao R; Liang K
Sci Adv; 2023 May; 9(20):eadf8698. PubMed ID: 37205756
[TBL] [Abstract][Full Text] [Related]
34. Identification and characterization of the CDK12/cyclin L1 complex involved in alternative splicing regulation.
Chen HH; Wang YC; Fann MJ
Mol Cell Biol; 2006 Apr; 26(7):2736-45. PubMed ID: 16537916
[TBL] [Abstract][Full Text] [Related]
35. Cdk12 Is A Gene-Selective RNA Polymerase II Kinase That Regulates a Subset of the Transcriptome, Including Nrf2 Target Genes.
Li X; Chatterjee N; Spirohn K; Boutros M; Bohmann D
Sci Rep; 2016 Feb; 6():21455. PubMed ID: 26911346
[TBL] [Abstract][Full Text] [Related]
36. CDK12 Activity-Dependent Phosphorylation Events in Human Cells.
Bartkowiak B; Yan CM; Soderblom EJ; Greenleaf AL
Biomolecules; 2019 Oct; 9(10):. PubMed ID: 31652541
[TBL] [Abstract][Full Text] [Related]
37. The structure and substrate specificity of human Cdk12/Cyclin K.
Bösken CA; Farnung L; Hintermair C; Merzel Schachter M; Vogel-Bachmayr K; Blazek D; Anand K; Fisher RP; Eick D; Geyer M
Nat Commun; 2014 Mar; 5():3505. PubMed ID: 24662513
[TBL] [Abstract][Full Text] [Related]
38. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program.
Gomes NP; Bjerke G; Llorente B; Szostek SA; Emerson BM; Espinosa JM
Genes Dev; 2006 Mar; 20(5):601-12. PubMed ID: 16510875
[TBL] [Abstract][Full Text] [Related]
39. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
[TBL] [Abstract][Full Text] [Related]
40. Chemical inhibitors of transcription-associated kinases.
Clopper KC; Taatjes DJ
Curr Opin Chem Biol; 2022 Oct; 70():102186. PubMed ID: 35926294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
